Using the Cholinergic Anti-Inflammatory Pathway to Treat Systemic Lupus Musculoskeletal Pain
不适用
已完成
NCT02822989
| 适应症 | Lupus Erythematosus, Systemic, Musculoskeletal Pain |
|---|
| 分期 | 不适用 |
|---|
| 申办方 | Northwell Health |
|---|
| 状态 | 已完成 |
|---|
| 受试者人数 | 19 人 |
|---|
| 干预(药物) | Vagus nerve stimulation, Sham vagus nerve stimulation |
|---|
| 开始日期 | 2017年11月1日 |
|---|
| 完成日期 | 2018年4月30日 |
|---|
| 结果公布日 | 2026年7月8日 |
|---|
摘要
Systemic Lupus Erythematosus (SLE) is a chronic autoimmune, inflammatory disease and musculoskeletal pain is one of the most common symptoms. This study will investigate whether transcutaneous stimulation of the vagus nerve will decrease lupus musculoskeletal pain. This study will additionally investigate the biologic effects of vagus nerve stimulation on inflammation. It will be the first clinical study using one of the body's own pathways of modulating the immune system and inflammatory response, the cholinergic anti-inflammatory pathway, in SLE.
Change in Musculoskeletal Pain From Baseline.
5 days · units on a scale
| Vagus Nerve Stimulation | -5.00 units on a scale |
|---|
| Sham Vagus Nerve Stimulation | 0.10 units on a scale |
|---|
Percentage of Subjects With Treatment Emergent Adverse Events.
12 days · Participants
| Vagus Nerve Stimulation | 1 Participants |
|---|
| Sham Vagus Nerve Stimulation | 0.00 Participants |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
同一适应症的其他试验
全部试验
本页整理自 ClinicalTrials.gov 的公开数据,不构成医疗建议,也不构成投资建议。请务必咨询专业医师。